1
|
Bardakci M, Karakas H, Bayram D, Avci N, Kitapli S, Ozen M, Aslan F, Koseoglu C, Kadioglu A, Onur ID, Sakalar T, Buyuksimsek M, Alkan A, Ergun Y, Kaya AO, Bilgin B, Yalcin B. Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment. Sci Rep 2024; 14:10632. [PMID: 38724585 PMCID: PMC11082209 DOI: 10.1038/s41598-024-61562-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Accepted: 05/07/2024] [Indexed: 05/12/2024] Open
Abstract
While some clinics have adopted abbreviated neoadjuvant treatment for HER2-positive breast cancer, there remains a shortage of comprehensive clinical data to support this practice. This is a retrospective, multicenter study. A total of 142 patients were included in the study who are HER2-positive breast cancer, aged ≤ 65 years, with left ventricular ejection fraction ≥ 50%, received neoadjuvant chemotherapy and underwent surgery at 10 different oncology centers in Türkiye between October 2016 and December 2022. The treatment arms were divided into 4-6 cycles of docetaxel/trastuzumab/pertuzumab for arm A, 4 cycles of adriamycin/cyclophosphamide followed by 4 cycles of taxane/TP for arm B. There were 50 patients (35.2%) in arm A and 92 patients (64.8%) in arm B. The median follow-up of all of the patients was 19.9 months (95% CI 17.5-22.3). The 3-year DFS rates for treatment arms A and B were 90.0% and 83.8%, respectively, and the survival outcomes between the groups were similar (p = 0.34). Furthermore, the pathologic complete response rates were similar in both treatment arms, at 50.0% and 51.1%, respectively (p = 0.90). This study supports shortened neoadjuvant treatment of HER2-positive breast cancer, a common practice in some clinics.
Collapse
Affiliation(s)
- Murat Bardakci
- Department of Medical Oncology, Ankara City Hospital, 1604. Street, No: 9, 06000, Ankara, Turkey.
| | - Hilal Karakas
- Department of Medical Oncology, Ankara City Hospital, 1604. Street, No: 9, 06000, Ankara, Turkey
| | - Dogan Bayram
- Department of Medical Oncology, Ankara City Hospital, 1604. Street, No: 9, 06000, Ankara, Turkey
| | - Nilufer Avci
- Department of Medical Oncology, Medicana Bursa Hospital, Bursa, Turkey
| | - Sait Kitapli
- Department of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey
| | - Mirac Ozen
- Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey
| | - Ferit Aslan
- Department of Medical Oncology, Medicalpark Ankara Batikent Hospital, Ankara, Turkey
| | - Caglar Koseoglu
- Department of Medical Oncology, Ankara Gülhane Training and Research Hospital, Ankara, Turkey
| | - Ahmet Kadioglu
- Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Ilknur D Onur
- Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Teoman Sakalar
- Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey
| | - Mahmut Buyuksimsek
- Department of Medical Oncology, Adana City Training and Research Hospital, Adana, Turkey
| | - Ali Alkan
- Department of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey
| | - Yakup Ergun
- Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey
| | - Ali O Kaya
- Department of Medical Oncology, Medicana International Beylikduzu Hospital, Istanbul, Turkey
| | - Burak Bilgin
- Department of Medical Oncology, Ankara City Hospital, 1604. Street, No: 9, 06000, Ankara, Turkey
| | - Bulent Yalcin
- Department of Medical Oncology, Ankara City Hospital, 1604. Street, No: 9, 06000, Ankara, Turkey
| |
Collapse
|
2
|
Yildirim HC, Kapar C, Koksal B, Seyyar M, Sanci PC, Guliyev M, Perkin P, Buyukkor M, Yaslikaya S, Majidova N, Keskinkilic M, Ozaskin D, Avci T, Gunes TK, Arcagok M, Topal A, Keskin GSY, Kavgaci G, Yildirim N, Celayir OM, Avci N, Aslan F, Alkan A, Erciyestepe M, Cengiz M, Pehlivan M, Gulmez A, Beypinar I, Basoglu Tuylu T, Kayikcioglu E, Chalabiyev E, Turhal S, Guzel HG, Ayas E, Sahbazlar M, Dulgar O, Demir H, Yavuzsen T, Bayoglu V, Kivrak Salim D, Ozturk B, Ozdemir F, Kara O, Oksuzoglu B, Bal O, Demirci NS, Yilmaz M, Cabuk D, Aksoy S. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study. J Chemother 2024:1-7. [PMID: 38497444 DOI: 10.1080/1120009x.2024.2330835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Accepted: 03/11/2024] [Indexed: 03/19/2024]
Abstract
The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of palbociclib is limited. Data are also limited regarding the effectiveness of CDK 4-6 inhibitors in patients whose dose was reduced due to neutropenia, the most common side effect of CDK 4-6 inhibitors. In our study, we aimed to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment in patients with premenopausal metastatic breast cancer and the effect of dose reduction due to neutropenia on progression-free survival. Our study is a multicenter, retrospective study, and factors affecting progression-free survival (PFS) were examined in patients diagnosed with metastatic premenopausal breast cancer from 29 different centers and receiving combination therapy containing palbociclib or ribociclib in the metastatic stage. 319 patients were included in the study. The mPFS for patients treated with palbociclib was 26.83 months, and for those receiving ribociclib, the mPFS was 29.86 months (p = 0.924). mPFS was 32.00 months in patients who received a reduced dose, and mPFS was 25.96 months in patients who could take the initial dose, and there was no statistical difference (p = 0.238). Liver metastasis, using a fulvestrant together with a CDK 4-6 inhibitor, ECOG PS 1 was found to be a negative prognostic factor. No new adverse events were observed. In our study, we found PFS over 27 months in patients diagnosed with premenopausal breast cancer with CDK 4-6 inhibitors used in first-line treatment, similar to post-menopausal patients. We did not detect any difference between the effectiveness of the two CDK 4-6 inhibitors, and we showed that there was no decrease in the effectiveness of the CDK 4-6 inhibitor in patients whose dose was reduced due to neutropenia.
Collapse
Affiliation(s)
- Hasan Cagri Yildirim
- Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
- Department of Medical Oncology, Nigde Research and Education Hospital, Nigde, Turkey
| | - Caner Kapar
- Department of Medical Oncology, Bakırkoy Dr. Sadi Konuk Education and Research Hospital, İstanbul, Turkey
| | - Baris Koksal
- Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
| | - Mustafa Seyyar
- Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Pervin Can Sanci
- Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Murad Guliyev
- Department of Medical Oncology, Istanbul Cerrahpasa University Faculty of Medicine, Istanbul, Turkey
| | - Perihan Perkin
- Department of Medical Oncology, Yildirim Beyazit University, Bilkent State Hospital, Ankara, Turkey
| | - Mustafa Buyukkor
- Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Ankara, Turkey
| | - Sendag Yaslikaya
- Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey
| | - Nargiz Majidova
- Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey
| | - Merve Keskinkilic
- Department of Medical Oncology, 9 Eylül University Faculty of Medicine, Izmir, Turkey
| | - Duygu Ozaskin
- Department of Medical Oncology, Afyon Health Sciences University School of Medicine, Afyonkarahisar, Turkey
| | - Tugay Avci
- Department of Medical Oncology, Celal Bayar University Faculty of Medicine, Manisa, Turkey
| | - Tugce Kubra Gunes
- Department of Medical Oncology, Umraniye Research and Education Hospital, Istanbul, Turkey
| | - Murat Arcagok
- Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkey
| | - Alper Topal
- Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkey
| | - Gul Sema Yildiran Keskin
- Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara, Turkey
| | - Gozde Kavgaci
- Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
| | - Nilgun Yildirim
- Department of Medical Oncology, Firat University Faculty of Medicine, Elazig, Turkey
| | - Ozde Melisa Celayir
- Department of Medical Oncology, Acibadem University Faculty of Medicine, Istanbul, Turkey
| | - Nilufer Avci
- Department of Medical Oncology, Medicana Hospital, Bursa, Turkey
| | - Ferit Aslan
- Department of Medical Oncology, Medical Park Ankara Hospital, Ankara, Turkey
| | - Ali Alkan
- Department of Medical Oncology, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Turkey
| | - Mert Erciyestepe
- Department of Medical Oncology, Istanbul Prof. Dr. Cemil Tascioglu State Hospital, Istanbul, Turkey
| | - Muhammet Cengiz
- Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey
| | - Metin Pehlivan
- Department of Medical Oncology, Zonguldak Ataturk State Hospital, Zonguldak, Turkey
| | - Ahmet Gulmez
- Department of Medical Oncology, Adana City Education and Research Hospital, Adana, Turkey
| | - Ismail Beypinar
- Department of Medical Oncology, Alaaddin Keykubat University Faculty of Medicine, Antalya, Turkey
| | - Tugba Basoglu Tuylu
- Department of Medical Oncology, Nigde Research and Education Hospital, Nigde, Turkey
| | - Erkan Kayikcioglu
- Department of Medical Oncology, Isparta Suleyman Demirel University Faculty of Medicine, Isparta, Turkey
| | - Elvin Chalabiyev
- Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
| | - Serdal Turhal
- Department of Medical Oncology, Anadolu Health Center, Istanbul, Turkey
| | - Halil Goksel Guzel
- Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey
| | - Eyyup Ayas
- Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey
| | - Mustafa Sahbazlar
- Department of Medical Oncology, Celal Bayar University Faculty of Medicine, Manisa, Turkey
| | - Ozgecan Dulgar
- Department of Medical Oncology, Umraniye Research and Education Hospital, Istanbul, Turkey
| | - Hacer Demir
- Department of Medical Oncology, Afyon Health Sciences University School of Medicine, Afyonkarahisar, Turkey
| | - Tugba Yavuzsen
- Department of Medical Oncology, 9 Eylül University Faculty of Medicine, Izmir, Turkey
| | - Vedat Bayoglu
- Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey
| | - Derya Kivrak Salim
- Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey
| | - Banu Ozturk
- Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey
| | - Feyyaz Ozdemir
- Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey
| | - Oguz Kara
- Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey
| | - Berna Oksuzoglu
- Department of Medical Oncology, Dr. A. Y. Ankara Oncology Research and Education Hospital, University of Health Sciences, Ankara, Turkey
| | - Oznur Bal
- Department of Medical Oncology, Yildirim Beyazit University, Bilkent State Hospital, Ankara, Turkey
| | - Nebi Serkan Demirci
- Department of Medical Oncology, Istanbul Cerrahpasa University Faculty of Medicine, Istanbul, Turkey
| | - Mesut Yilmaz
- Department of Medical Oncology, Bakırkoy Dr. Sadi Konuk Education and Research Hospital, İstanbul, Turkey
| | - Devrim Cabuk
- Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Sercan Aksoy
- Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
| |
Collapse
|
3
|
Benlice C, Koc MA, Gulcu B, Bilgin IA, Akyol C, Baca B, Ozturk E, Guney Y, Utkan G, Er O, Agaoglu F, Yildirim I, Avci N, Elhan AH, Kuzu MA. Short-Course Radiotherapy Followed by Consolidation Chemotherapy Is Safe and Effective in Locally Advanced Rectal Cancer: Comparative Short-term Results of Multicenter Propensity Score Case-Matched Study. Dis Colon Rectum 2023; 66:681-690. [PMID: 36856669 DOI: 10.1097/dcr.0000000000002646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
BACKGROUND Consolidation chemotherapy strategies have demonstrated improved pathological complete response and tumor downstaging rates for patients diagnosed with rectal cancer. OBJECTIVE This study aimed to compare perioperative outcomes and pathological complete response rates among different neoadjuvant treatment strategies in patients undergoing total mesorectal excision for locally advanced rectal cancer. DESIGN Propensity score case-matched study. SETTING High-volume tertiary care centers. PATIENTS Consecutive patients undergoing curative total mesorectal excision between January 2014 and June 2021 were queried. INTERVENTIONS Patients were divided into 3 groups: long-course chemoradiation therapy with (N = 128) or without (N = 164) consolidation chemotherapy or short-course radiotherapy (N = 53) followed by consolidation chemotherapy. MAIN OUTCOME MEASURES Demographics, preoperative tumor characteristics, histopathologic outcomes, and postoperative complication rates were reviewed and compared. Propensity score match analysis was conducted. RESULTS A total of 345 patients (mean age: 58 ± 12 years; female: 36%) met the study inclusion criteria. Time interval from neoadjuvant treatment until surgery was longer for patients receiving consolidation chemotherapy ( p < 0.001). Pathological complete response rates were comparable among patients receiving long-course chemoradiation therapy (20.3%) and short-course radiotherapy with consolidation chemotherapy (20.8%) compared to long-course chemoradiation therapy alone (14.6%) ( p = 0.36). After the propensity score case-matched analysis, 48 patients in the long-course chemoradiation therapy with consolidation chemotherapy group were matched to 48 patients in the short-course radiotherapy with consolidation chemotherapy group. Groups were comparable with respect to age, sex, clinical stage, tumor location, type of surgical approach, and technique. Pathological complete response rate was comparable between the groups (20.8% and 18.8%, p = 0.99). LIMITATIONS Study was limited by its retrospective nature. CONCLUSIONS Among recent neoadjuvant treatment modalities, pathological complete response rates, and short-term clinical outcomes were comparable. Short-course radiotherapy with consolidation chemotherapy is safe and effective as long-course chemoradiation therapy as in a short-term period. See Video Abstract at http://links.lww.com/DCR/C174 . LA RADIOTERAPIA DE CORTA DURACIN SEGUIDA DE QUIMIOTERAPIA DE CONSOLIDACIN ES SEGURA Y EFICAZ EN EL CNCER DE RECTO LOCALMENTE AVANZADO RESULTADOS COMPARATIVOS A CORTO PLAZO DEL ESTUDIO MULTICNTRICO DE CASOS EMPAREJADOS POR PUNTAJE DE PROPENSION ANTECEDENTES: Las estrategias de quimioterapia de consolidación han demostrado una mejor respuesta patológica completa y tasas de reducción del estadio del tumor para pacientes diagnosticados con cáncer de recto.OBJETIVO: Comparar los resultados perioperatorios y las tasas de respuesta patológica completa entre diferentes estrategias de tratamiento neoadyuvante en pacientes sometidos a escisión mesorrectal total por cáncer de recto localmente avanzado.DISEÑO: Estudio de casos emparejados por puntaje de propensión.ENTORNO CLINICO: Centros de atención terciaria de alto volumen.PACIENTES: Pacientes consecutivos sometidos a escisión mesorrectal total curativa por cáncer de recto localmente avanzado entre enero de 2014 y junio de 2021.INTERVENCIONES: Los pacientes se dividieron en tres grupos según la modalidad de tratamiento neoadyuvante: quimiorradioterapia de ciclo largo con (N = 128) o sin (N = 164) quimioterapia de consolidación o radioterapia de ciclo corto (N = 53) seguida de quimioterapia de consolidación.PRINCIPALES MEDIDAS DE RESULTADO: El punto final primario fue la respuesta patológica completa. Se revisaron y compararon los datos demográficos, las características preoperatorias del tumor, los resultados histopatológicos y las tasas de complicaciones posoperatorias entre los grupos de estudio. Se realizó un análisis de casos emparejados por puntaje de propensión.RESULTADOS: Un total de 345 pacientes (edad media de 58 ± 12 años y mujeres: 36%) cumplieron los criterios de inclusión del estudio. El intervalo de tiempo desde el tratamiento neoadyuvante hasta la cirugía fue mayor para los pacientes que recibieron quimioterapia de consolidación ( p < 0,001). Las tasas de respuesta patológica completa fueron comparables entre los pacientes que recibieron quimiorradioterapia de larga duración con quimioterapia de consolidación (20,3 %) y radioterapia de corta duración con quimioterapia de consolidación (20,8%) en comparación con la quimiorradiación de larga duración sola (14,6%) ( p = 0,36). Después del análisis de casos emparejados por puntaje de propensión, 48 pacientes en el grupo de quimiorradioterapia de ciclo largo con quimioterapia de consolidación se emparejaron con 48 pacientes en el grupo de radioterapia de ciclo corto con quimioterapia de consolidación. Los grupos fueron comparables con respecto a la edad, sexo, estadio clínico, ubicación del tumor, tipo de abordaje quirúrgico y la técnica. La tasa de respuesta patológica completa fue comparable entre los grupos (20,8% y 18,8%, p = 0,99). La morbilidad postoperatoria a los 30 días y las tasas de fuga anastomótica fueron similares.LIMITACIONES: El estudio estuvo limitado por su naturaleza retrospectiva.CONCLUSIONES: Entre las modalidades de tratamiento neoadyuvante recientes, las tasas de respuesta patológica completa y los resultados clínicos a corto plazo fueron comparables. La radioterapia de corta duración con quimioterapia de consolidación es segura y eficaz como terapia de quimiorradioterapia de larga duración en un período corto. Consulte Video Resumen en http://links.lww.com/DCR/C174 . (Traducción-Dr. Fidel Ruiz Healy ).
Collapse
Affiliation(s)
- Cigdem Benlice
- Department of General Surgery, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Mehmet Ali Koc
- Department of General Surgery, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Baris Gulcu
- Department of General Surgery, Bursa Medicana Hospital, Bursa, Turkey
| | - Ismail Ahmet Bilgin
- Department of General Surgery, Faculty of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
| | - Cihangir Akyol
- Department of General Surgery, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Bilgi Baca
- Department of General Surgery, Faculty of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
| | - Ersin Ozturk
- Department of General Surgery, Bursa Medicana Hospital, Bursa, Turkey
| | - Yildiz Guney
- Department of Radiation Oncology, Yuksek Ihtisas University, Memorial Ankara Hospital, Ankara, Turkey
| | - Gungor Utkan
- Department of Medical Oncology, Ankara University, Ankara, Turkey
| | - Ozlem Er
- Department of Medical Oncology, Faculty of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
| | - Fulya Agaoglu
- Department of Radiation Oncology, Faculty of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey
| | - Ibrahim Yildirim
- Department of Radiation Oncology, Bursa Medicana Hospital, Bursa, Turkey
| | - Nilufer Avci
- Department of Medical Oncology, Bursa Medicana Hospital, Bursa, Turkey
| | - Atilla Halil Elhan
- Department of Biostatistics; Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Mehmet Ayhan Kuzu
- Department of General Surgery, Faculty of Medicine, Ankara University, Ankara, Turkey
| |
Collapse
|
4
|
Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, Turhal S. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. Cancer Invest 2021; 40:199-209. [PMID: 34894960 DOI: 10.1080/07357907.2021.2017952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
PURPOSE This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. METHODS Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. RESULTS The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). CONCLUSION We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.
Collapse
Affiliation(s)
- Ahmet Bilici
- Department of Medical Oncology, Medical Faculty, Medipol University, Bagcilar, Turkey
| | - Mukremin Uysal
- Department of Medical Oncology, Medical Faculty, Afyon Kocatepe University, Afyon, Turkey
| | - Serkan Menekse
- Department of Medical Oncology, Manisa State Hospital, Manisa, Turkey
| | - Semih Akin
- Department of Medical Oncology, Medical Faculty, Ege University, Izmir, Turkey
| | - Fatih Yildiz
- Department of Medical Oncology, Dr Abdurrahman Yurtarslan Oncology Education and Research Hospital, Ankara, Turkey
| | - Merve Turan
- Department of Medical Oncology, Medical Faculty, Adnan Menderes University, Aydin, Turkey
| | - Sema Sezgin Goksu
- Department of Medical Oncology, Medical Faculty, Akdeniz University, Antalya, Turkey
| | - Ismail Beypinar
- Department of Medical Oncology, Medical Faculty, Afyon Kocatepe University, Afyon, Turkey
| | - Teoman Sakalar
- Department of Medical Oncology, Medical Faculty, Erciyes University, Kayseri, Turkey
| | - Mustafa Değirmenci
- Department of Medical Oncology, Izmir Tepecik Education and Research Hospital, Izmir, Turkey
| | - Dilek Erdem
- Department of Medical Oncology, Medical Faculty, Bahcesehir University, Samsun, Turkey
| | - Gul Basaran
- Department of Medical Oncology, Medical Faculty, Acibadem University, Istanbul, Turkey
| | - Omer Fatih Olmez
- Department of Medical Oncology, Medical Faculty, Medipol University, Bagcilar, Turkey
| | - Nilufer Avci
- Department of Medical Oncology, Medicana Bursa Hospital, Bursa, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Bakirkoy Dr Sadi Konuk Education and Research Hospital, Istanbul, Turkey
| | - Abdullah Sakin
- Department of Medical Oncology, Medical Faculty, Yuzuncuyil University, Van, Turkey
| | - Sema Turker
- Department of Medical Oncology, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey
| | - Atakan Demir
- Department of Medical Oncology, Medical Faculty, Acibadem University, Istanbul, Turkey
| | - Suleyman Temiz
- Department of Medical Oncology, Kocaeli Acıbadem Hospital, Kocaeli, Turkey
| | - Muhammed Ali Kaplan
- Department of Medical Oncology, Medical Faculty, Dicle University, Diyarbakir, Turkey
| | - Mutlu Dogan
- Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey
| | - Ozgur Tanriverdi
- Department of Medical Oncology, Medical Faculty, Mugla Sitki Kocman University, Mugla, Turkey
| | - Irem Bilgetekin
- Department of Medical Oncology, Medical Faculty, Gazi University, Ankara, Turkey
| | - Havva Yesil Cinkir
- Department of Medical Oncology, Medical Faculty, Gaziantep University, Gaziantep, Turkey
| | - Ozgur Acikgoz
- Department of Medical Oncology, Medical Faculty, Medipol University, Bagcilar, Turkey
| | - Semra Paydas
- Department of Medical Oncology, Medical Faculty, Cukurova University, Adana, Turkey
| | - Ruchan Uslu
- Department of Medical Oncology, Medical Faculty, Ege University, Izmir, Turkey
| | - Serdar Turhal
- Anadolu Medical Center, Department of Medical Oncology, Istanbul, Turkey
| |
Collapse
|
5
|
Sengoz T, Avci N. 18F-FDG PET/CT Findings in Metastatic Pilomatrix Carcinoma. Clin Nucl Med 2020; 45:146-147. [PMID: 31833930 DOI: 10.1097/rlu.0000000000002857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
We describe a rare case of metastatic pilomatrix carcinoma with distant metastases 10 months after diagnosis. A 37-year-old woman was diagnosed with pilomatrix carcinoma by excisional biopsy from the occipital region and referred to us for F-FDG PET/CT examinations at the time of diagnosis and 10 months after diagnosis. The first PET/CT did not show any pathological activity, whereas the second PET/CT showed multiple intensive F-FDG uptakes in the right lung parenchyma, right hemithorax pleura, liver, and bones.
Collapse
Affiliation(s)
- Tarik Sengoz
- From the Department of Nuclear Medicine, Medical Faculty, Pamukkale University, Denizli
| | - Nilufer Avci
- Department of Medical Oncology, Medicana Hospital, Bursa, Turkey
| |
Collapse
|
6
|
Oktay E, Levent M, Gelincik H, Aktaş G, Yumuk F, Koral L, Arpacı E, Keser M, Alkan A, Karci E, Karadurmuş N, Degirmencioglu S, Turan M, Uyeturk U, Cabuk D, Avci N, Toprak O, Ergen A, Urvay S, Bayman E, Petekkaya E, Nayir E, Paydaş S, Yavuzsen T, Senler FC, Yaren A, Barutca S, Şahinler İ, Ozyilkan O, Tanriverdi O. Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). J Cancer Educ 2020; 35:69-75. [PMID: 30446981 DOI: 10.1007/s13187-018-1441-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Cancer is one of the most common causes of death all over the World (Rahib et al. in Cancer Res 74(11):2913-2921, 2014; Silbermann et al. in Ann Oncol 23(Suppl 3):iii15-iii28, 2012). It is crucial to diagnose this disease early by effective screening methods and also it is very important to acknowledge the community on various aspects of this disease such as the treatment methods and palliative care. Not only the oncologists but every medical doctor should be educated well in dealing with cancer patients. Previous studies suggested various opinions on the level of oncology education in medical schools (Pavlidis et al. in Ann Oncol 16(5):840-841, 2005). In this study, the perspectives of medical students on cancer, its treatment, palliative care, and the oncologists were analyzed in relation to their educational status. A multicenter survey analysis was performed on a total of 4224 medical school students that accepted to enter this study in Turkey. After the questions about the demographical characteristics of the students, their perspectives on the definition, diagnosis, screening, and treatment methods of cancer and their way of understanding metastatic disease as well as palliative care were analyzed. The questionnaire includes questions with answers and a scoring system of Likert type 5 (absolutely disagree = 1, completely agree = 5). In the last part of the questionnaire, there were some words to detect what the words "cancer" and "oncologist" meant for the students. The participant students were analyzed in two study groups; "group 1" (n = 1.255) were phases I and II students that had never attended an oncology lesson, and "group 2" (n = 2.969) were phases III to VI students that had attended oncology lessons in the medical school. SPSS v17 was used for the database and statistical analyses. A value of p < 0.05 was noted as statistically significant. Group 1 defined cancer as a contagious disease (p = 0.00025), they believed that early diagnosis was never possible (p = 0.042), all people with a diagnosis of cancer would certainly die (p = 0.044), and chemotherapy was not successful in a metastatic disease (p = 0.003) as compared to group 2. The rate of the students that believed gastric cancer screening was a part of the national screening policy was significantly more in group 1 than in group 2 (p = 0.00014). Group 2 had a higher anxiety level for themselves or their family members to become a cancer patient. Most of the students in both groups defined medical oncologists as warriors (57% in group 1 and 40% in group 2; p = 0.097), and cancer was reminding them of "death" (54% in group 1 and 48% in group 2; p = 0.102). This study suggested that oncology education was useful for the students' understanding of cancer and related issues; however, the level of oncology education should be improved in medical schools in Turkey. This would be helpful for medical doctors to cope with many aspects of cancer as a major health care problem in this country.
Collapse
Affiliation(s)
- Esin Oktay
- Faculty of Medicine, Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey.
| | - Mustafa Levent
- Faculty of Medicine, Department of Internal Medicine, Sıtkı Kocman University, Mugla, Turkey
| | - Hakan Gelincik
- Faculty of Medicine, Department of Medical Oncology, Cukurova University, Adana, Turkey
| | - Gizem Aktaş
- Faculty of Medicine, Department of Medical Oncology, Cukurova University, Adana, Turkey
| | - Fulden Yumuk
- Faculty of Medicine, Department of Medical Oncology, Marmara University, Istanbul, Turkey
| | - Lokman Koral
- Faculty of Medicine, Department of Medical Oncology, Onsekiz Mart University, Canakkale, Turkey
| | - Erkan Arpacı
- Faculty of Medicine, Department of Medical Oncology, Sakarya University, Sakarya, Turkey
| | - Murat Keser
- Faculty of Medicine, Department of Medical Oncolog, Dokuz Eylul University, Izmir, Turkey
| | - Ali Alkan
- Faculty of Medicine, Department of MedicalOncology, Ankara University, Ankara, Turkey
| | - Ebru Karci
- Department of Medical Oncology, Gulhane Military Medical Academy, Ankara, Turkey
| | - Nuri Karadurmuş
- Department of Medical Oncology, Gulhane Military Medical Academy, Ankara, Turkey
| | - Serkan Degirmencioglu
- Faculty of Medicine, Department of Medical Oncology, Pamukkale University, Denizli, Turkey
| | - Merve Turan
- Faculty of Medicine, Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey
| | - Ummugul Uyeturk
- Faculty of Medicine, Department of Medical Oncology, Izzet Baysal University, Bolu, Turkey
| | - Devrim Cabuk
- Faculty of Medicine, Department of Medical Oncology, Kocaeli University, Izmit, Turkey
| | - Nilufer Avci
- Faculty of Medicine, Department of Medical Oncology, Balıkesir University, Balıkesir, Turkey
| | - Omer Toprak
- Faculty of Medicine, Department of Internal Medicine, Balıkesir University, Balıkesir, Turkey
| | - Arzu Ergen
- Cerrahpasa Faculty of Medicine, Department of Radiation Oncology, Istanbul University, Istanbul, Turkey
| | - Semiha Urvay
- Faculty of Medicine, Department of Medical Oncology, Cumhuriyet University, Sivas, Turkey
| | - Evrim Bayman
- Faculty of Medicine, Department of Radiation Oncology, Osmangazi University, Eskisehir, Turkey
| | - Emine Petekkaya
- Faculty of Medicine, Department of Anatomy, Beykent University, Istanbul, Turkey
| | - Erdinç Nayir
- Department of Medical Oncology, Mersin Medicalpark Hospital, Mersin, Turkey
| | - Semra Paydaş
- Faculty of Medicine, Department of Medical Oncology, Cukurova University, Adana, Turkey
| | - Tugba Yavuzsen
- Faculty of Medicine, Department of Medical Oncolog, Dokuz Eylul University, Izmir, Turkey
| | - Filiz Cay Senler
- Faculty of Medicine, Department of MedicalOncology, Ankara University, Ankara, Turkey
| | - Arzu Yaren
- Faculty of Medicine, Department of Medical Oncology, Pamukkale University, Denizli, Turkey
| | - Sabri Barutca
- Faculty of Medicine, Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey
| | - İsmet Şahinler
- Cerrahpasa Faculty of Medicine, Department of Radiation Oncology, Istanbul University, Istanbul, Turkey
| | - Ozgur Ozyilkan
- Faculty of Medicine, Department of Medical Oncology, Başkent University, Ankara, Turkey
| | - Ozgur Tanriverdi
- Faculty of Medicine, Department of Medical Oncology, Mugla Sıtkı Kocman University, Mugla, Turkey
| |
Collapse
|
7
|
Bilici A, Menekse S, Akin S, Degirmenci M, Olmez OF, Avci N, Sakalar T, Tural D, Kaplan MA, Tanriverdi O, Bilgetekin I, Uslu R. Abstract P6-18-37: The efficacy and safety analysis of the treatments of everolimus and exemestane combination in 101 metastatic breast cancer patients: Real-life experience from Turkey. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Endocrine treatment and chemotherapy are a treatment options for patients with hormone receptor (HR) positive and HER2-negative metastatic breast cancer (MBC). However, response to first-line hormone treatment could not obtained in all patients, and even patients who havea response will eventually relapse. After disease progression, second-line hormonal treatmentoptions are used sequentially. Everolimus with exemestane has demonstrated promising activity in patients with HR-positive HER2-negative endocrine-resistant MBC with respect to the results of the BOLERO-2 study. In the present study, we aimed to evaluate the efficacy and safety of this combination in the real-life clinical setting for the unselected population in Turkey. Material and Methods: One hundred and one patients with HR-positive HER-2 negative MBC progressing after prior endocrine treatment who were treated with everolimus with exemestane were retrospectively analyzed. The tolerability and efficacy of this combination were evaluated in the unselected Turkish patients. Results: Among 101 patients, 45% of patients had visceral and %50 patients had only bone metastasis. Everolimus with exemestane treatment was administered as a second-line in 21.3% of patients, third-line in 40.4% and forth-line and later in 38.2%. The objective response rate was 24.7% (CR+PR) and stable disease was obtained in 37.7% of patients. At the median follow-up time of 13.5 months, the median progression-free survival (PFS) time and 1-year PFS were 13.8 months and 57.2%, while the median overall survival (OS) interval and 1-year OS were 40 months and 85%. The median treatment duration was 8.3 and 6.5 months for exemestane and everolimus, respectively. The most frequent reason for discontinuation of treatment were disease progression (39%). Moreover, the most common advers events (AE) causing permanent discontinuation were stomatitis (3%) and pneumonitis (3%). A total of 81 % of patients experienced at least one AE of any grade, 25% of patients at least one grade 3 or 4 AE. Due to AEs, everolimus dosage was reduced to 5 mg in 16 (15.8%) of patients. Conclusions: Our findings confirmed that the combination of everolimus with exemestane was the safe and effective treatment options for patients with HR-positive HER-2 negative MBC after second or later lines treatments.
Citation Format: Bilici A, Menekse S, Akin S, Degirmenci M, Olmez OF, Avci N, Sakalar T, Tural D, Kaplan MA, Tanriverdi O, Bilgetekin I, Uslu R. The efficacy and safety analysis of the treatments of everolimus and exemestane combination in 101 metastatic breast cancer patients: Real-life experience from Turkey [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-37.
Collapse
Affiliation(s)
- A Bilici
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - S Menekse
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - S Akin
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - M Degirmenci
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - OF Olmez
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - N Avci
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - T Sakalar
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - D Tural
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - MA Kaplan
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - O Tanriverdi
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - I Bilgetekin
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| | - R Uslu
- Medipol University, Medical Faculty, Istanbul, Turkey; Bagcilar Education and Research Hospital, Istanbul, Turkey; Ege University, Medical Faculty, Izmir, Turkey; Izmir Tepecik Education and Research Hospital, Izmir, Turkey; Ali Osman Sonmez Oncology Hospital, Bursa, Turkey; Erciyes University, Medical Faculty, Kayser, Turkey; Bakirkoy Sadi Konuk Education and Research Hospital, Istanbul, Turkey; Dicle University, Medical Faculty, Diyarbakir, Turkey; Mugla Sitki Kocman University, Medical Faculty, Mugla, Turkey; Gazi University, Medical Faculty, Ankara, Turkey
| |
Collapse
|
8
|
Ozturk A, Celik S, Kodaz H, Yildiz I, Ocak A, Hacibekiroglu I, Bayoglu I, Ercelep O, Ekinci A, Menekse S, Gumusay O, Oven B, Aldemir M, Geredeli C, Baykara M, Uysal M, Sevinc A, Aksoy A, Ulas A, Inanc M, Tanriverdi O, Avci N, Turan N, Gumus M. P3.01-33 EGFR Mutation in Patients with NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Kanat O, Cubukcu E, Avci N, Budak F, Ercan I, Canhoroz M, Olmez F. Comparison of Three Different Treatment Modalities in the Management of Cancer Cachexia. Tumori 2018; 99:229-33. [DOI: 10.1177/030089161309900218] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background The optimal treatment of cancer cachexia remains unknown. In this study, we compared the efficacy of three different treatment modalities in the management of cancer cachexia. Methods Sixty-two assessable cachectic cancer patients were randomized to one of the following three arms: 1) megesterol acetate (MA) plus meloxicam (n = 23); 2) MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21); or 3) meloxicam plus oral EPA-enriched nutritional supplement (n = 18). Treatment duration was 3 months. Results The treatment arms were well balanced at baseline. The primary efficacy (body weight and lean body mass) and secondary efficacy (body mass index, quality of life, and serum levels of IL-6 and TNF-α) parameters improved after treatment in all three arms. There were no statistically significant differences between treatment groups in the mean percentage changes in all efficacy parameters from baseline to end of study. Conclusions MA plus meloxicam or EPA supplement plus meloxicam may be effective treatment options in the management of cancer cachexia. The combined use of these agents does not provide further advantages.
Collapse
Affiliation(s)
- Ozkan Kanat
- Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey
| | - Erdem Cubukcu
- Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey
| | - Nilufer Avci
- Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey
| | - Ferah Budak
- Immunology Unit, Department of Microbiology and Infectious Disease, Uludag University Faculty of Medicine, Bursa, Turkey
| | - Ilker Ercan
- Department of Biostatistics, Uludag University Faculty of Medicine, Bursa, Turkey
| | - Mustafa Canhoroz
- Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey
| | - Fatih Olmez
- Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey
| |
Collapse
|
10
|
Aksoy A, Odabas H, Kaya S, Bozkurt O, Degirmenci M, Topcu TO, Aytekin A, Arpaci E, Avci N, Pilanci KN, Cinkir HY, Bozkaya Y, Cirak Y, Gumus M. Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort. Saudi Med J 2017; 38:156-162. [PMID: 28133688 PMCID: PMC5329627 DOI: 10.15537/smj.2017.2.18055] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Objectives: To analyze the relationship between clinical features, hormonal receptor status, and survival in patients who were diagnosed with medullary breast cancer (MBC). Methods: Demographic characteristics, histopathological features, and survival statuses of 201 patients diagnosed with MBC between 1995 and 2015 were retrospectively recorded. Survival analyses were conducted with uni- and multivariate cox regression analysis. Results: Median follow-up time was 54 (4-272) months. Median patient age at the time of diagnosis was 47 years old (26-90). Of the patients, 91.5% were triple negative. Five-year recurrence free survival time (RFS) rate was 87.4% and overalll survival (OS) rate 95.7%. For RFS, progesterone receptor (PR) negativity, atypical histopathological evaluation, absence of lymphovascular invasion, smaller tumor, lower nodal involvement were found to be favourable prognostic factors by univariate analysis (p<0.05). The PR negativity and smaller tumor were found to be favourable factors by univariate analysis (p<0.05). However, none of these factors were determined as significant independent prognostic factors for OS (p>0.05). Conclusion: Turkish MBC patients exhibited good prognosis, which was comparable with survival outcomes achieved in the literature. The PR negativity was related to a better RFS and OS rates.
Collapse
Affiliation(s)
- Asude Aksoy
- Department of Medical Oncology, Medical Faculty, Firat University Elazig, Turkey. E-mail.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Affiliation(s)
- S. Oglak
- Labour Economics and Industrial Relationship, Adnan Menderes University, Aydin, Turkey,
| | - A. Canatan
- Gazi University Department of Sociology, Ankara, Turkey,
| | - I. Tufan
- Akdeniz University, Department of Gerontology, Antalya, Turkey,
| | - S. Acar
- Municipality of Dinar, Mayor of Dinar, Afyon, Turkey,
| | - N. Avci
- Adana Residential Care and Rehabilitation Center, Adana, Turkey
| |
Collapse
|
12
|
Artac M, Korkmaz L, Coskun H, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan F, Doruk H, Avci N, Turhal S. Efficacy of obesity in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy combinations: A Turkish Oncology Group Study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Tanriverdi O, Yilmaz EM, Menekse S, Cokmert S, Oktay E, Pilanci KN, Kocar M, Avci N, Akman T, Goksel G, Meydan N, Barutca S. The recurrence with isolated intra-abdominal lymph node in patients with colorectal cancer: A study of the Turkish Descriptive Oncological Researches Group (intra-abdominal lymph node and colon cancer). Journal of Oncological Sciences 2016. [DOI: 10.1016/j.jons.2016.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
14
|
Tanriverdi O, Menekse S, Teker F, Oktay E, Nur Pilanc K, Gunaldi M, Kocar M, Kacan T, Bahceci A, Avci N, Akman T, Cokmert S, Yesil-Cinkir H, Teoman Yanmaz M. The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG). J BUON 2016; 21:840-850. [PMID: 27685904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
PURPOSE To determine the predictive value of the mean platelet volume (MPV) and the MPV/platelet count ratio on the development of isolated bone metastasis in patients with breast cancer. METHODS A total of 121 previously untreated female patients with isolated bone metastases from breast cancer (group 1) were included in this retrospective cohort study. The patients enrolled in this study had similar age, biological subtypes, and duration of follow-up after diagnosis. Group 1 was compared with both 71 previously untreated women with breast cancer with no metastases at all (group 2) and 39 healthy women (group 3). Demographic data, laboratory tests and histological features of all of the patients in groups 1 and 2 were recorded and the study variables from each of the three groups were compared. RESULTS In group 1, the cut-off value (9.2 fL) for the MPV was determined and patients were stratified into 4 subgroups. The MPV was higher in group 1 than in either group 2 or group 3. Group 1 patients had a MPV of 8.8±3.1 fL (mean 5.1, range: 6.1-15.6) and the cut-off value for MPV was 9.2 fl. For patients in group 1, the MPV distribution was stratified into 4 groups as follows: group A included MPV values <6.08 fL, in group B values ranged from 6.09 to 8.46 fL, group C included values from 8.47 to 10.05 fL, and group D included patients with MPV values >10.06 fL. MPV and the presence of lymphovascular invasion were found to be independent risk factors for the development of isolated bone metastases. CONCLUSION We concluded that MPV can be used to predict the development of isolated bone metastases.
Collapse
Affiliation(s)
- Ozgur Tanriverdi
- Mugla Sitki Kocman University Faculty of Medicine, Department of Medical Oncology, Mugla, Turkey
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Tanriverdi O, Avci N, Oktay E, Kalemci S, Pilanci KN, Cokmert S, Menekse S, Kocar M, Sen CA, Akman T, Ordu C, Goksel G, Meydan N, Barutca S. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group. Asian Pac J Cancer Prev 2016; 16:5971-6. [PMID: 26320482 DOI: 10.7314/apjcp.2015.16.14.5971] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Several prognostic factors have been studied in NSCLC, although it is unknown which is most useful. In this study, we aimed to investigate whether pre-treatment serum albumin level has prognostic value in patients with Stage IIIB NSCLC. MATERIALS AND METHODS This cross-sectional study included a total of 204 patients with Stage IIIB NSCLC who met the inclusion criteria. Pre-treatment serum albumin levels and demographic, clinical, and histological characteristics, as well as laboratory variables were recorded. A cut-off value was defined for serum albumin level and the patients were stratified into four groups on thios basis. RESULTS The majority of the patients was males and smokers, with a history of weight loss, and squamous histological type of lung cancer. The mean serum albumin level was 3.2±1.7 g/dL (range, 2.11-4.36 g/dL). A cut-off value 3.11 g/dL was set and among the patients with a lower level, 68% had adenocarcinoma and 82% were smokers. The patients with low serum albumin levels had a lower response rate to e first-line chemotherapy with a shorter progression-free survival and overall survival. Multivariate analysis showed that low serum albumin level was an independent poor prognostic factor for NSCLC. CONCLUSIONS This study results suggest that low serum albumin level is an independent poor prognostic factor in patients with Stage IIIB NSCLC, associated with reduction in the response rate to first-line therapy and survival rates.
Collapse
Affiliation(s)
- Ozgur Tanriverdi
- Department of Medical Oncology, Sitki Kocman University Faculty of Medicine, Mugla, Turkey E-mail :
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Nayir E, Tanriverdi O, Karakas Y, Kilickap S, Serdar Turhal N, Avci N, Okutur K, Koca D, Erdem D, Abali H, Yamac D, Bilir C, Kacan T. Tendency of cancer patients and their relatives to use internet for health-related searches: Turkish Oncology Group (TOG) Study. J BUON 2016; 21:714-719. [PMID: 27569068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
PURPOSE This study aimed to reveal the habits of using internet by cancer patients and their relatives to access health-related information and services in Turkey. METHODS An 18-item questionnaire survey was applied in cancer patients and their relatives. RESULTS A total of 1106 patients (male, 37.3%, and female, 62.7%) and their relatives were included in the study. The responders had been using internet to obtain health information about oncological diseases, once a month (34.2%), 1-2 times a week (27.4%) or 2-3 times a month (21.9%). After diagnosis of cancer was made, participants more frequently (64.4%) investigated health-related issues, while 64.9% of them considered internet as an important search tool, and 16.7% of them had thought to give up cancer therapy under the influence of internet information. Some (33.1%) participants had used herbal medicine, and 16.7% of them had learnt these herbal products from internet. Still 12.7% of them had not questioned the accuracy of internet information, while 26.9% of them indicated that they had not shared the internet information about cancer with their physicians, and 13 % of them searched information in internet without asking their physicians. CONCLUSION Cancer patients and their relatives showed a higher tendency to use health-related internet information which may mislead them, and can result in treatment incompliance. Health professionals should offer evidence-based information to the patients and their relatives through internet.
Collapse
Affiliation(s)
- Erdinc Nayir
- Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkey
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Deligonul A, Evrensel T, Avci N, Ugras N, Ture M, Cubukcu E, Hartavi M, Fatih Olmez O, Kurt E, Tolunay S, Kanat O, Manavoglu O. Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer. J BUON 2016; 21:564-9. [PMID: 27569073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/28/2022]
Abstract
PURPOSE The clinical value of HER4 - a cell surface receptor that belongs to the human epidermal growth factor receptor family - for predicting survival outcomes in patients with breast cancer remains controversial. Herein, we sought to investigate the prognostic significance of HER4 immunohistochemical expression with respect to progression-free survival (PFS) and overall survival (OS) in Turkish patients with metastatic breast cancer (MBC). METHODS MBC patients (N=45; mean age=50.5±12.7 years) were consecutively enrolled between 2000 and 2006 in the Department of Oncology at the Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections. The predictive value of HER4 expression was investigated by multivariate analysis after allowance for potential confounders. RESULTS The mean PFS in the study participants was 11.35 months (range:1-50), whereas the median OS was 22.18 months (range:1-76). The mean PFS in patients with a HER4 immunohistochemical score of 0, 1+, 2+, and 3+ was 11.0 ± 4.8, 11.3 ± 7.7, 11.7 ± 8.1, and 10.4 ± 7.4 months, respectively (p=0.99) . The mean OS in patients with a HER4 score of 0, 1+, 2+, and 3+ was 13.3 ± 6.8, 25.6 ± 10.8, 22.9 ± 10.7, and 13.5 ± 9.9, months, respectively (p=0.44). The results of multivariate Cox regression analysis indicated that the presence of visceral metastases was the only independent prognostic factor for both OS (HR=3.01, 95% CI=1.56-3.99, p <0.01) and PFS (HR=2.91, 95% CI=1.51-3.78, p <0.01). CONCLUSION HER4 immunohistochemical expression is not an independent predictor of OS and PFS in Turkish MBC patients.
Collapse
Affiliation(s)
- Adem Deligonul
- Department of Oncology, Uludag University of Medicine, Bursa, Turkey
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Ulas A, Silay K, Akinci S, Dede DS, Akinci MB, Sendur MAN, Cubukcu E, Coskun HS, Degirmenci M, Utkan G, Ozdemir N, Isikdogan A, Buyukcelik A, Inanc M, Bilici A, Odabasi H, Cihan S, Avci N, Yalcin B. Medication errors in chemotherapy preparation and administration: a survey conducted among oncology nurses in Turkey. Asian Pac J Cancer Prev 2016; 16:1699-705. [PMID: 25773812 DOI: 10.7314/apjcp.2015.16.5.1699] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Medication errors in oncology may cause severe clinical problems due to low therapeutic indices and high toxicity of chemotherapeutic agents. We aimed to investigate unintentional medication errors and underlying factors during chemotherapy preparation and administration based on a systematic survey conducted to reflect oncology nurses experience. MATERIALS AND METHODS This study was conducted in 18 adult chemotherapy units with volunteer participation of 206 nurses. A survey developed by primary investigators and medication errors (MAEs) defined preventable errors during prescription of medication, ordering, preparation or administration. The survey consisted of 4 parts: demographic features of nurses; workload of chemotherapy units; errors and their estimated monthly number during chemotherapy preparation and administration; and evaluation of the possible factors responsible from ME. The survey was conducted by face to face interview and data analyses were performed with descriptive statistics. Chi-square or Fisher exact tests were used for a comparative analysis of categorical data. RESULTS Some 83.4% of the 210 nurses reported one or more than one error during chemotherapy preparation and administration. Prescribing or ordering wrong doses by physicians (65.7%) and noncompliance with administration sequences during chemotherapy administration (50.5%) were the most common errors. The most common estimated average monthly error was not following the administration sequence of the chemotherapeutic agents (4.1 times/month, range 1-20). The most important underlying reasons for medication errors were heavy workload (49.7%) and insufficient number of staff (36.5%). CONCLUSIONS Our findings suggest that the probability of medication error is very high during chemotherapy preparation and administration, the most common involving prescribing and ordering errors. Further studies must address the strategies to minimize medication error in chemotherapy receiving patients, determine sufficient protective measures and establishing multistep control mechanisms.
Collapse
Affiliation(s)
- Arife Ulas
- Department of Medical Oncology, Ankara Ataturk Training and Research Hospital, Ankara, Turkey E-mail :
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Avci N, Hayar M, Altmisdortoglu O, Tanriverdi O, Deligonul A, Ordu C, Evrensel T. Smoking habits are an independent prognostic factor in patients with lung cancer. The Clinical Respiratory Journal 2015; 11:579-584. [DOI: 10.1111/crj.12386] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2015] [Revised: 08/13/2015] [Accepted: 09/07/2015] [Indexed: 02/04/2023]
Affiliation(s)
- Nilufer Avci
- Department of Medical Oncology; State Hospital; Balikesir Turkey
| | - Murat Hayar
- Department of Radiation Oncology; State Hospital; Balikesir Turkey
| | | | - Ozgur Tanriverdi
- Department of Medical Oncology; Mugla Sitki Kocman University Faculty of Medicine; Mugla Turkey
| | - Adem Deligonul
- Department of Medical Oncology; Uludag University Faculty of Medicine; Bursa Turkey
| | - Cetin Ordu
- Department of Medical Oncology; State Hospital; Balikesir Turkey
| | - Turkkan Evrensel
- Department of Medical Oncology; Uludag University Faculty of Medicine; Bursa Turkey
| |
Collapse
|
20
|
Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Altmisdortoglu O, Tanriverdi O, Aksoy A, Kurt E, Evrensel T. Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy. J BUON 2015; 20:994-1000. [PMID: 26416041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
PURPOSE The presence of a pronounced tumor lymphocytic infiltrate (TLI) is deemed to reflect the presence of an immunoinflammatory response against the tumor and may thus have prognostic significance. We investigated the prognostic value of TLI detected in pathological specimens collected following neoadjuvant chemotherapy (NACT) in patients with breast cancer. METHODS 100 consecutive patients with breast cancer (mean age 47.8±11.4 years) who were scheduled to undergo anthracycline-and/or taxane-containing NACT were enrolled. Specimens collected after NACT were scored with the 4-point Klintrup scoring criteria for the presence of TLI. RESULTS 60 patients had low-grade TLI and 40 high-grade TLI. Comparison of the patient population according to low-grade vs high-grade TLI revealed statistically significant difference both in terms of disease-free survival (DFS) (log rank-4.28, p<0.05) and overall survival (OS) (log rank=3.96, p<0.05), with high-grade TLI patients showing a better prognosis. Multivariate Cox regression analysis identified postoperative tumor size and low-grade TLI as the two main independent adverse prognostic factors. CONCLUSION High-grade TLI may interfer with tumor growth and can represent a favorable prognostic factor in women with breast cancer undergoing NACT.
Collapse
Affiliation(s)
- Nilufer Avci
- Department of Medical Oncology, Ali Osman Sonmez Oncology Hospital, Bursa, Turkey
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Coskun U, Altundag K, Aliustaoglu M, Uncu D, Ozkan M, Cicin I, Ciltas A, Elkiran T, Kocer M, Isikdogan A, Karaoglu A, Tekin SB, Avci N, Ulas A, Oksuzoglu B, Ozdemir F, Dumanli E, Sevinc A, Kilickap S, Benekli M. Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e12657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Ugur Coskun
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
| | - Kadri Altundag
- Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey
| | - Mehmet Aliustaoglu
- Dr. Lütfi Kirdar Kartal Training and Research Hospital, Istanbul, Turkey
| | - Dogan Uncu
- Ankara Numune Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Metin Ozkan
- Erciyes University Faculty of Medicine Department of Medical Oncology, Kayseri, Turkey
| | - Irfan Cicin
- Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey
| | | | - Tamer Elkiran
- Inonu University Faculty of Medicine, Malatya, Turkey
| | - Murat Kocer
- Suleyman Demirel University, Isparta, Turkey
| | | | | | | | | | - Arife Ulas
- Education and Research Hospital, Bursa, Turkey
| | - Berna Oksuzoglu
- Ankara Oncology Research and Training Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Feyyaz Ozdemir
- Karadeniz Technical University School of Medicine, Trabzon, Turkey
| | | | - Alper Sevinc
- Gaziantep University Faculty of Medicine, Department of Medical Oncology, Gaziantep, Turkey
| | | | - Mustafa Benekli
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
| | - Ruchan Uslu, Ozgur Ozyilkan, Bulent Yalcin, Melih Cem Boruban, Faysal Dane, Oguz Kara, Gamze Gokoz Dogu, Banu Ozturk, Ali Osman Kaya, Mahmut Gumus, Hande Turna
| |
Collapse
|
22
|
Altundag K, Dumanli E, Aliustaoglu M, Uncu D, Ozkan M, Cicin I, Coskun U, Elkiran T, Kocer M, Isikdogan A, Karaoglu A, Tekin SB, Avci N, Ulas A, Oksuzoglu B, Ozdemir F, Kilickap S, Gumus M, Buyukberber S, Benekli M. Turkish National Breast Cancer Registry. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e12654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Kadri Altundag
- Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey
| | | | | | - Dogan Uncu
- Ankara Numune Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Metin Ozkan
- Medical Oncology Department, Erciyes University, Kayseri, Turkey
| | - Irfan Cicin
- Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey
| | - Ugur Coskun
- Gazi University Tip Fakultesi, Ankara, Turkey
| | - Tamer Elkiran
- Inonu University Faculty of Medicine, Malatya, Turkey
| | - Murat Kocer
- Suleyman Demirel University, Isparta, Turkey
| | | | | | | | | | - Arife Ulas
- Ali Osman Sonmez Oncology Hospital, Department of Medical Oncology, Bursa, Turkey
| | - Berna Oksuzoglu
- Ankara Oncology Research and Training Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Feyyaz Ozdemir
- Karadeniz Technical University School of Medicine, Trabzon, Turkey
| | | | - Mahmut Gumus
- Kartal Research and Training Hospital, Istanbul, Turkey
| | - Suleyman Buyukberber
- Gazi University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| | - Mustafa Benekli
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
| | - Faysal Dane, Alper Sevinc, Melih Cem Boruban, Hande Turna, Ruchan Uslu, Ozgur Ozyilkan, Bulent Yalcin, Oguz Kara, Gamze Gokoz Dogu, Banu Ozturk, Ali Osman Kaya
| |
Collapse
|
23
|
Ulas A, Kos T, Avci N, Cubukcu E, Olmez OF, Bulut N, Degirmenci M. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival. Asian Pac J Cancer Prev 2015; 16:1643-9. [PMID: 25743846 DOI: 10.7314/apjcp.2015.16.4.1643] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The aim of the present study was to evaluate clinicopathological characteristics of our early stage breast cancer patients who are epidermal growth factor receptor 2 (HER2) overexpressed/ amplified (HER2+), the efficacy of trastuzumab treatment and survival results. MATERIALS AND METHODS Patients with HER2- positive early stage breast cancer receiving adjuvant trastuzumab were investigated retrospectively. Clinicopathological features of 210 patients and treatment outcome were analysed. To evaluate survival rates, the Kaplan-Meier method was used. Univariate and multivariate analyses were conducted with the Cox regression model. RESULTS Mean age of the patients was 51.8, 71.9% being postmenopausal. Some 37.6% of patients were node negative, and 31% had T1 tumor size and 52.4% were positive for estrogen receptor. Of 210 patients, 89.5% completed planned 52 weeks adjuvant trastuzumab treatment. The median follow up was 27.5 months (6.0-86.0 ). Relapse free survival (RFS) was 68.0 months (95% CI: 62.1-74.0) and overall survival (OS) was 74.8 months (95% CI: 69.5-80.1). The 3 year OS for all patients was 92.0% and RFS was 79.6%. During follow up, relapse was detected at the rate of 14.3%. Trastuzumab associated cardiotoxicity was found at the rate of 3.3%. In univariate analyses, larger tumor size and grade III were significantly associated (p<0.05) with RFS. Multivariate analyses of covariates displaying p<0.05 identified grade III as an independent prognostic factor. CONCLUSIONS In the present study, it was established that trastuzumab had a satisfactory safety profile and treatment efficacy as in other clinical studies and that among clinicopathological factors evaluated, only being grade 3 had a significant effect on RFS. The occurrence of relapse with adjuvant trastuzumab makes it necessary to identify molecular predictors, which will define this group better and help explain resistance to anti HER2 based therapies.
Collapse
Affiliation(s)
- Arife Ulas
- Department of Medical Oncology, Ankara Ataturk Training and Research Hospital, Ankara, Turkey E-mail :
| | | | | | | | | | | | | |
Collapse
|
24
|
Unal OU, Oztop I, Yasar N, Urakci Z, Ozatli T, Bozkurt O, Sevinc A, Gunaydin Y, Yapar Taskoylu B, Arpaci E, Ulas A, Kodaz H, Tonyali O, Avci N, Aksoy A, Yilmaz AU. Clinicopathologic characteristics, treatment outcomes, and prognostic factors of primary thoracic soft tissue sarcoma: A multicenter study of the Anatolian Society of Medical Oncology (ASMO). Thorac Cancer 2015; 6:85-90. [PMID: 26273340 PMCID: PMC4448466 DOI: 10.1111/1759-7714.12150] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Accepted: 06/23/2014] [Indexed: 12/28/2022] Open
Abstract
Background Soft tissue sarcomas (STSs) are rare malignant tumors of embryogenic mesoderm origin. Primary thoracic STSs account for a small percentage of all STSs and limited published information is available. This study aimed to identify the prognostic factors for thoracic STSs and evaluate the disease's clinical outcomes. Methods The medical records of 109 patients with thoracic STSs who were treated between 2003 and 2013 were retrospectively reviewed. Patients' survival rates were analyzed and potential prognostic factors evaluated. Results The median follow-up period was 29 months (range: 1–121 months). STSs were most frequently localized on the chest wall (n = 42; 38.5%) and lungs (n = 42; 38.5%). The most common histological types were malignant fibrous histiocytoma (n = 23; 21.1%), liposarcoma (n = 17; 15.6%), and leiomyosarcoma (n = 16; 14.7%). The median survival time of all patients was 40.3 months (95% confidence interval, 14.22–66.37 months), with one and five-year survival rates of 93.4% and 63.5%, respectively. Univariate analysis of all groups revealed that metastatic stage, unresectability, tumor diameter of >10 cm, tumor location other than the chest wall, and grade 3 diseases were predictable of poor survival. However, only grade 3 diseases and tumor location other than the chest wall were confirmed by multivariate analysis as poor prognostic factors. Conclusions Primary thoracic STSs are rarely seen malignant tumors. Our results indicated that patients with low-grade tumors and those localized on the chest wall often experienced better survival outcomes.
Collapse
Affiliation(s)
- Olcun Umit Unal
- Division of Medical Oncology, Department of Internal Medicine, Ataturk University Medical Faculty Erzurum, Turkey
| | - Ilhan Oztop
- Division of Medical Oncology, Department of Internal Medicine, Dokuz Eylul University Medical Faculty Izmir, Turkey
| | - Nurgul Yasar
- Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital Istanbul, Turkey
| | - Zuhat Urakci
- Department of Medical Oncology, Dicle University Faculty of Medicine Diyarbakir, Turkey
| | - Tahsin Ozatli
- Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Training and Research Hospital Ankara, Turkey
| | - Oktay Bozkurt
- Department of Medical Oncology, Erciyes University Faculty of Medicine Kayseri, Turkey
| | - Alper Sevinc
- Department of Medical Oncology, Gaziantep University Faculty of Medicine Gaziantep, Turkey
| | - Yusuf Gunaydin
- Department of Medical Oncology, Gazi University Faculty of Medicine Ankara, Turkey
| | - Burcu Yapar Taskoylu
- Department of Medical Oncology, Pamukkale University Faculty of Medicine Denizli, Turkey
| | - Erkan Arpaci
- Department of Medical Oncology, Sakarya Education and Research Hospital Sakarya, Turkey
| | - Arife Ulas
- Department of Medical Oncology, Ali Sonmez Oncology Hospital Bursa, Turkey
| | - Hilmi Kodaz
- Department of Medical Oncology, Trakya University Faculty of Medicine Edirne, Turkey
| | - Onder Tonyali
- Department of Medical Oncology, Gazi University Faculty of Medicine Ankara, Turkey
| | - Nilufer Avci
- Department of Medical Oncology, Balikesir Goverment Hospital Balikesir, Turkey
| | - Asude Aksoy
- Department of Medical Oncology, Firat University Faculty of Medicine Elazig, Turkey
| | - Ahmet Ugur Yilmaz
- Department of Medical Oncology, Izmir University Faculty of Medicine Izmir, Turkey
| |
Collapse
|
25
|
Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A, Hartavi M, Kurt E, Evrensel T. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON 2015; 20:45-49. [PMID: 25778295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
PURPOSE The impact of neoadjuvant chemotherapy (NACT) on immunohistochemical markers in breast cancer specimens remains controversial. We designed the current study to investigate the potential changes in estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67 expression before and after NACT in a cohort of Turkish patients with breast cancer. METHODS This research was designed as a prospective, observational study of 100 consecutive patients with breast cancer (mean age 47.8±11.4 years) who were scheduled to undergo anthracycline- and/or taxane-containing NACT before attempting cytoreductive surgery at the Department of Oncology of the Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded specimens. RESULTS Changes in immunohistochemical markers before and after NACT were only significant for HER-2 and Ki- 67. More specifically, the number of HER-2-positive specimens decreased from 21 before NACT to 8 after NACT (p<0.001). Similarly, the number of tumor samples positive for Ki-67 decreased significantly from 65 to 24 after NACT (p<0.001). Mean pre- and post-treatment tumor grades of differentiation before and after NACT were 2.56 ± 0.67 and 2.37±1.07, respectively (p<0.05). We did not find any significant associations between baseline ER, PR, HER2, and Ki-67 expression with both overall survival (OS) and disease- free survival (DFS). CONCLUSION Our study suggests that NACT reduces the expression of HER2 and Ki-67 in breast cancer specimens. The significance of NACT-induced changes in the immunohistochemical expression of HER2 and Ki-67 in patients with breast cancer should be further studied in future translational and clinical research.
Collapse
Affiliation(s)
- Nilufer Avci
- Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Ulas A, Turkoz FP, Silay K, Tokluoglu S, Avci N, Oksuzoglu B, Alkis N. A laboratory prognostic index model for patients with advanced non-small cell lung cancer. PLoS One 2014; 9:e114471. [PMID: 25474743 PMCID: PMC4256446 DOI: 10.1371/journal.pone.0114471] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Accepted: 11/11/2014] [Indexed: 11/22/2022] Open
Abstract
Purpose We aimed to establish a laboratory prognostic index (LPI) in advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze the predictive value of LPI on NSCLC survival. Patients and Methods The study retrospectively reviewed 462 patients with advanced NSCLC diagnosed between 2000 and 2010 in a single institution. We developed an LPI that included serum levels of white blood cells (WBC), lactate dehydrogenase (LDH), albumin, calcium, and alkaline phosphatase (ALP), based on the results of a Cox regression analysis. The patients were classified into 3 LPI groups as follows: LPI 0: normal; LPI 1: one abnormal laboratory finding; and LPI 2: at least 2 abnormal laboratory findings. Results The median follow up period was 44 months; the median overall survival (OS) and median progression-free survival (PFS) were 11 and 6 months, respectively. A multivariate analysis revealed that the following could be used as independent prognostic factors: an Eastern Cooperative Oncology Group performance status score (ECOG PS) ≥2, a high LDH level, serum albumin <3 g/dL, serum calcium>10.5 g/dL, number of metastases>2, presence of liver metastases, malignant pleural effusion, or receiving chemotherapy ≥4 cycles. The 1-year OS rates according to LPI 0, LPI 1, and LPI 2 were 54%, 34%, and 17% (p<0.001), respectively and 6-month PFS rates were 44%, 27%, and 15% (p<0.001), respectively. The LPI was a significant predictor for OS (Hazard Ratio (HR): 1.41; 1.05–1.88, p<0.001) and PFS (HR: 1.48; 1.14–1.93, p<0.001). Conclusion An LPI is an inexpensive, easily accessible and independent prognostic index for advanced NSCLC and may be helpful in making individualized treatment plans and predicting survival rates when combined with clinical parameters.
Collapse
Affiliation(s)
- Arife Ulas
- Department of Medical Oncology, Ankara Ataturk Training and Research Hospital, Ankara, Turkey
- * E-mail:
| | - Fatma Paksoy Turkoz
- Department of Medical Oncology, Ankara Oncology Teaching and Research Hospital, Ankara, Turkey
| | - Kamile Silay
- Department of Internal Medicine and Geriatrics, Yildirim Beyazit University, Faculty of Medicine, Ataturk Research and Training Hospital, Ankara, Turkey
| | - Saadet Tokluoglu
- Department of Medical Oncology, Ankara Oncology Teaching and Research Hospital, Ankara, Turkey
| | - Nilufer Avci
- Department of Medical Oncology, Balıkesir Government Hospital, Balıkesir, Turkey
| | - Berna Oksuzoglu
- Department of Medical Oncology, Ankara Oncology Teaching and Research Hospital, Ankara, Turkey
| | - Necati Alkis
- Department of Medical Oncology, Ankara Oncology Teaching and Research Hospital, Ankara, Turkey
| |
Collapse
|
27
|
Hartavi M, Kurt E, Oral B, Olmez OF, Cubukcu E, Deligonul A, Avci N, Manavoglu O. The SOCS-1 -1478CA/del polymorphism is not associated with colorectal cancer or age at onset in Turkish subjects. Asian Pac J Cancer Prev 2014; 14:7583-6. [PMID: 24460337 DOI: 10.7314/apjcp.2013.14.12.7583] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Suppressor of cytokine signaling (SOCS)-1 acts as a key regulator of many cytokine signaling pathways and its abnormal expression has been identified in several human malignancies, suggesting potential roles in carcinogenesis. The aim of this study was to investigate any association between the functional SOCS- 1 -1478CA>del polymorphism and colorectal cancer (CC) as well as age at onset in a Turkish clinical sample. MATERIALS AND METHODS A total of 122 subjects were enrolled in this case-control study (70 CC cases and 52 controls). The SOCS-1 -1478CA>del polymorphism was genotyped using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. RESULTS The odds ratio of the del allele for CC relative to the CA allele was not significantly different between the groups (OR=0.71, 95% CI=0.41-1.22, p=0.27). This result did not change after adjustment for age and sex on multivariable regression analysis (OR=0.84, 95% CI=0.59-1.34, p=0.53). When the SOCS-1 -1478CA>del polymorphism was analyzed among CC patients in relation to the age at disease onset, we found no significant differences between subjects with the del/del, CA/del, and CA/CA genotypes. CONCLUSIONS The results of our study did not point towards a major role of the SOCS-1 -1478CA>del polymorphism in the pathogenesis of CC in Turkish subjects.
Collapse
Affiliation(s)
- Mustafa Hartavi
- Department of Internal Medicine, Uludag University, Faculty of Medicine, Bursa, Turkey E-mail :
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Tanriverdi O, Cokmert S, Oktay E, Pilanci KN, Menekse S, Kocar M, Sen CA, Avci N, Akman T, Ordu C, Goksel G, Meydan N. Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group. Med Oncol 2014; 31:217. [DOI: 10.1007/s12032-014-0217-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Accepted: 09/02/2014] [Indexed: 12/16/2022]
|
29
|
Tanriverdi O, Kaytan-Saglam E, Ulger S, Bayoglu IV, Turker I, Ozturk-Topcu T, Cokmert S, Turhal S, Oktay E, Karabulut B, Kilic D, Kucukzeybek Y, Oksuzoglu B, Meydan N, Kaya V, Akman T, Ibis K, Saynak M, Sen CA, Uysal-Sonmez O, Pilancı KN, Demir G, Saglam S, Kocar M, Menekse S, Goksel G, Yapar-Taskoylu B, Yaren A, Uyeturk U, Avci N, Denizli B, Ilis-Temiz E. The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG). Med Oncol 2014; 31:152. [PMID: 25108599 DOI: 10.1007/s12032-014-0152-z] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Accepted: 07/28/2014] [Indexed: 02/01/2023]
Abstract
Brain metastasis in colorectal cancer is highly rare. In the present study, we aimed to determine the frequency of brain metastasis in colorectal cancer patients and to establish prognostic characteristics of colorectal cancer patients with brain metastasis. In this cross-sectional study, the medical files of colorectal cancer patients with brain metastases who were definitely diagnosed by histopathologically were retrospectively reviewed. Brain metastasis was detected in 2.7 % (n = 133) of 4,864 colorectal cancer patients. The majority of cases were male (53 %), older than 65 years (59 %), with rectum cancer (56 %), a poorly differentiated tumor (70 %); had adenocarcinoma histology (97 %), and metachronous metastasis (86 %); received chemotherapy at least once for metastatic disease before brain metastasis developed (72 %), had progression with lung metastasis before (51 %), and 26 % (n = 31) of patients with extracranial disease at time the diagnosis of brain metastasis had both lung and bone metastases. The mean follow-up duration was 51 months (range 5-92), and the mean survival was 25.8 months (95 % CI 20.4-29.3). Overall survival rates were 81 % in the first year, 42.3 % in the third year, and 15.7 % in the fifth year. In multiple variable analysis, the most important independent risk factor for overall survival was determined as the presence of lung metastasis (HR 1.43, 95 % CI 1.27-4.14; P = 0.012). Brain metastasis develops late in the period of colorectal cancer and prognosis in these patients is poor. However, early screening of brain metastases in patients with lung metastasis may improve survival outcomes with new treatment modalities.
Collapse
Affiliation(s)
- Ozgur Tanriverdi
- Department of Medical Oncology, Faculty of Medicine, Medical School of Sitki Kocman University, Mugla, 48000, Turkey,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Yildiz I, Ekenel M, Akman T, Kocar M, Uysal M, Kanitez M, Varol U, Bayoglu IV, Tural D, Kaplan MA, Avci N, Sürmeli Z, Dede İ, Ulaş A, Yazici O, Basaran M. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. Anticancer Res 2014; 34:4329-4334. [PMID: 25075067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM This study aimed to assess the clinical efficacy and toxicity of sunitinib, a targeted-agent, for non-clear cell renal cell carcinoma. PATIENTS AND METHODS Sixty-three patients with complete clinical data from 13 oncology Centers were retrospectively evaluated. Outcomes analyzed were objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse events. RESULTS The median age of all patients, 38 men (60.3%) and 25 women (39.7%), was 63 years (range=25-82 years). Histological subtypes included 46 (88%) cases of papillary RCC, 10 of chromophobe, and 7 unclassified cases. Median treatment duration was seven months (range=2-86 months). At the time of this analysis, 52 patients had discontinued treatment, 33 of whom had died. Treatment discontinuation was due to disease progression in 43 patients, and toxicity in nine. Dose interruption was necessary in 22 (34.9%) patients, and dose reduction in 27 (42.9%). The objective response rate and disease control rate were 11.1% and 63.5%, respectively. The median PFS and OS were 7.6 months (95% confidence interval (CI)=5.5-9.7 months) and 22.0 months (95% CI=13.4-30.6 months), respectively, with 1-year rates of 64.7% and 33.7%, respectively. CONCLUSION Clinical outcome of the metastatic non-clear cell RCC patients with sunitinib treatment seemed to be worse than the historical data of clear cell RCC patients, in terms of PFS, OS and objective response. New and more effective targeted-therapies and better understanding of the underlying molecular processes are necessary to improve survival outcome for these patients.
Collapse
Affiliation(s)
- Ibrahim Yildiz
- Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Meltem Ekenel
- Departments of Medical Oncology at: Institute of Oncology, Istanbul University, Istanbul, Turkey
| | - Tulay Akman
- Departments of Medical Oncology at: Izmir Tepecik Training and Research Hospital, Izmir, Turkey
| | - Muharrem Kocar
- Departments of Medical Oncology at: Sanliurfa Education and Research Hospital, Sanliurfa, Turkey
| | - Mükremin Uysal
- Departments of Medical Oncology at: Afyon Kocatepe University, Afyonkarahisar, Turkey
| | - Metin Kanitez
- Departments of Medical Oncology at: Marmara University Hospital, Istanbul, Turkey
| | - Umut Varol
- Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Ibrahim Vedat Bayoglu
- Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Deniz Tural
- Departments of Medical Oncology at: Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Mehmet Ali Kaplan
- Departments of Medical Oncology at: Dicle University, Diyarbakir, Turkey
| | - Nilufer Avci
- Departments of Medical Oncology at: Balikesir State Hospital, Balikesir, Turkey
| | - Zeki Sürmeli
- Departments of Medical Oncology at: Ege University, Tulay Aktas Oncology Hospital, Izmir, Turkey
| | - İsa Dede
- Departments of Medical Oncology at: Ankara University Medical Faculty, Ankara, Turkey
| | - Arife Ulaş
- Departments of Medical Oncology at: Ali Osman Sonmez Oncology Training and Research Hospital, Bursa, Turkey
| | - Ozan Yazici
- Departments of Medical Oncology at: Ankara Numune Education and Research Hospital, Ankara, Turkey
| | - Mert Basaran
- Departments of Medical Oncology at: Institute of Oncology, Istanbul University, Istanbul, Turkey
| |
Collapse
|
31
|
Cecener G, Egeli U, Tunca B, Erturk E, Ak S, Gokgoz S, Tasdelen I, Tezcan G, Demirdogen E, Bayram N, Avci N, Evrensel T. BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients. Cancer Invest 2014; 32:375-87. [PMID: 24884828 DOI: 10.3109/07357907.2014.919302] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BRCA1/BRCA2 genes were screened in 117 patients with breast cancer by sequencing. Fourteen percent of patients tested positive for BRCA1/BRCA2 mutations. Four frame shift mutations, four pathogenic missense mutations, and 25 different sequence variations were detected. BRCA mutation positivity was significantly associated with Ki67 (p = .001). BRCA protein expressions were decreased in the patients harboring important mutations and polymorphisms (BRCA1;P508 stop, V1740G, Q1182R, Q1756P and BRCA2;V2466A) related with disease. Our findings contribute significantly to the types of germline BRCA1/BRCA2 mutations and their biological effects in Turkish women. These data could help guide the management of BRCA1/BRCA2 mutation-carrying patients when considering breast-conserving therapy.
Collapse
Affiliation(s)
- Gulsah Cecener
- Department of Medical Biology, Faculty of Medicine, University of Uludag, Turkey,1
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Avci N, Cecener G, Deligonul A, Erturk E, Tunca B, Egeli U, Tezcan G, Akyildiz EU, Bayram AS, Gebitekin C, Kurt E, Evrensel T. Molecular markers for patients with thymic malignancies: not feasible at present? Asian Pac J Cancer Prev 2014; 15:3457-60. [PMID: 24870739 DOI: 10.7314/apjcp.2014.15.8.3457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Thymomas and thymic carcinomas are rare malignancies and devising clinically effective molecular targeted therapies is a major clinical challenge. The aim of the study was to analyze BLC2 and vascular endothelial growth factor receptor (VEGFR) expression and KRAS and EGFR mutational status and to correlate them with the clinical characteristics of patients with thymomas and thymic carcinomas. MATERIALS AND METHODS A total of 62 patients (mean age: 50.4 ± 13.2 years) with thymomas and thymic carcinomas were enrolled. The expression of BLC2 and VEGFR in tumor cells and normal tissues was evaluated by RT-PCR. The mutational status of the KRAS and EGFR genes was investigated by PCR with sequence specific primers. RESULTS The BLC2 and VEGFR expression levels did not differ significantly between tumor and normal tissues. Moreover, there were no clearly pathogenic mutations in KRAS or EGFR genes in any tumor. None of the molecular markers were significantly related to clinical outcomes. CONCLUSIONS Changes in levels of expression of BLC2 and VEGFR do not appear to be involved in thymic tumorigenesis. Moreover, our data suggest that KRAS and EGFR mutations do not play a major role in the pathogenesis of thymomas and thymic carcinomas.
Collapse
Affiliation(s)
- Nilufer Avci
- Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey E-mail :
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Coskun U, Gumus M, Uncu D, Ozkan M, Cicin I, Altundag K, Elkiran T, Kocer M, Karaoglu A, Avci N, Ozdemir F, Cubukcu E, Boruban MC, Sevinc A, Oksuzoglu B, Turna H, Yalcin B, Dumanli E, Ozdener F, Benekli M. Turkish Breast Cancer Registry: A multicenter epidemiologic study. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e12518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Ugur Coskun
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
| | - Mahmut Gumus
- Dr. Lutfi Kirdar Kartal Education and Research Hospital, Department of Medical Oncology, Istanbul, Turkey
| | - Dogan Uncu
- Ankara Numune Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Metin Ozkan
- Erciyes University Faculty of Medicine Department of Medical Oncology, Kayseri, Turkey
| | - Irfan Cicin
- Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey
| | - Kadri Altundag
- Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey
| | - Tamer Elkiran
- Inonu University Faculty of Medicine, Malatya, Turkey
| | - Murat Kocer
- Suleyman Demirel University, Isparta, Turkey
| | - Aziz Karaoglu
- Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkey
| | | | - Feyyaz Ozdemir
- Karadeniz Technical University School of Medicine, Trabzon, Turkey
| | - Erdem Cubukcu
- Department of Medical Oncology, Ali Osman Sonmez Oncology Hospital, Bursa, Turkey
| | - Melih Cem Boruban
- Necmettin Erbakan University Meram Medical Faculty Department of Medical Oncology, Konya, Turkey
| | - Alper Sevinc
- Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| | - Berna Oksuzoglu
- Ankara Oncology Research and Training Hospital Department of Medical Oncology, Ankara, Turkey
| | - Hande Turna
- Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey
| | - Bulent Yalcin
- Department of Oncology, Yildirim Beyazit University School of Medicine, Ankara, Turkey
| | | | | | - Mustafa Benekli
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
| | | |
Collapse
|
34
|
Yildiz I, Ekenel M, Akman T, Kocar M, Uysal M, Kanitez M, Bayoglu V, Varol U, Tural D, Avci N, Kaplan MA, Surmeli Z, Dede I, Ulas A, Yazici O, Basaran M. Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e15602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Ibrahim Yildiz
- Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Meltem Ekenel
- Oncology of Institute, University of Istanbul, Istanbul, Turkey
| | - Tulay Akman
- Dokuz Eylul University Medicine Faculty, Izmir, Turkey
| | - Muharrem Kocar
- Marmara University Hospital Medical Oncology Department, Istanbul, Turkey
| | - Mukremin Uysal
- Department of Medical Oncology, Afyon Kocatepe University, Afyonkarahisar, Turkey
| | - Metin Kanitez
- Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey
| | - Vedat Bayoglu
- Ataturk Education and Research Hospital Medical Oncology Department, Izmýr, Turkey
| | - Umut Varol
- Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | | | | | - Zeki Surmeli
- Department of Medical Oncology, Ege University, Tulay Aktas Oncology Hospital, Izmir, Turkey
| | - Isa Dede
- Ankara University Medical Faculty Department of Medical Oncology, Ankara, Turkey
| | - Arife Ulas
- Ali Osman Sonmez Oncology Hospital, Department of Medical Oncology, Bursa, Turkey
| | - Ozan Yazici
- Ankara Numune Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Mert Basaran
- Institute of Oncology, Istanbul University, Istanbul, Turkey
| |
Collapse
|
35
|
Canhoroz M, Kanat O, Saraydaroglu O, Buluc E, Avci N, Cubukcu E, Olmez O, Manavoglu O. Clinical significance of adiponectin expression in colon cancer patients. J Cancer Res Ther 2014; 10:347-53. [PMID: 25022390 DOI: 10.4103/0973-1482.136634] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
Uyeturk U, Tatli AM, Gucuk S, Oksuzoglu B, Ulas A, Avci N, Ozbay MF, Gunduz S, Akinci MB, Salim DK, Sonmez OU, Akdag F, Ergenc H. Risk Factors for Stage IV Breast Cancer at the Time of Presentation in Turkey. Asian Pac J Cancer Prev 2013; 14:7445-9. [DOI: 10.7314/apjcp.2013.14.12.7445] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
37
|
Olmez OF, Evrensel T, Cubukcu E, Ugras N, Avci N, Canhoroz M, Deligonul A, Hartavi M, Olmez F, Cubukcu S, Tolunay S, Kurt E, Kanat O, Manavoglu O. Prognostic significance of human epidermal receptor (HER)- 3 immunohistochemical expression in patients with metastatic breast cancer. Asian Pac J Cancer Prev 2013; 14:4115-9. [PMID: 23991962 DOI: 10.7314/apjcp.2013.14.7.4115] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Previous reports have shown that human epidermal receptor (HER)-3 overexpression may be associated with poor prognosis in patients with breast cancer, but results have been conflicting. In this study, we sought to investigate the prognostic significance of HER-3 immunohistochemical expression in patients with metastatic breast cancer. METHODS We retrospectively analyzed HER-3 immunohistochemical expression profiles in 45 paraffin-embedded specimens from patients who had been treated between 1996 and 2006 in the Department of Oncology of the Uludag University School of Medicine, Bursa, Turkey. Membranous or cytoplasmic dominant expression patterns of HER-3 were analyzed using the Rajkumar score and a cytoplasmic 4-point scoring system, respectively. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures. RESULTS The median PFS in the study participants was 9 months (interquartile range: 4.5-13 months), whereas the median OS was 20 months (interquartile range: 7.5-28 months). Categorization of the patient population according to HER-3 positive immunohistochemical expression did not reveal any statistically significant difference in terms of both PFS (p=0.70) and OS (p=0.81). The results of multivariable Cox regression analysis indicated that tumor size was the only independent predictor of PFS, whereas estrogen and progesterone receptor status was independently associated with OS. CONCLUSIONS HER-3 immunohistochemical expression did not correlate with outcomes in Turkish patients with metastatic breast cancer. Although our results suggest that HER-3 expression in cancer specimens is not of prognostic significance, further prospective studies are warranted to confirm these results.
Collapse
Affiliation(s)
- Omer Fatih Olmez
- Department of Medical Oncology, Uludag University Medical School, Bursa, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Kanat O, Cubukcu E, Avci N, Budak F, Ercan I, Canhoroz M, Olmez F. Comparison of three different treatment modalities in the management of cancer cachexia. Tumori 2013. [PMID: 23748819 DOI: 10.1700/1283.14197] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS AND BACKGROUND The optimal treatment of cancer cachexia remains unknown. In this study, we compared the efficacy of three different treatment modalities in the management of cancer cachexia. METHODS Sixty-two assessable cachectic cancer patients were randomized to one of the following three arms: 1) megesterol acetate (MA) plus meloxicam (n = 23); 2) MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21); or 3) meloxicam plus oral EPA-enriched nutritional supplement (n = 18). Treatment duration was 3 months. RESULTS The treatment arms were well balanced at baseline. The primary efficacy (body weight and lean body mass) and secondary efficacy (body mass index, quality of life, and serum levels of IL-6 and TNF-α) parameters improved after treatment in all three arms. There were no statistically significant differences between treatment groups in the mean percentage changes in all efficacy parameters from baseline to end of study. CONCLUSIONS MA plus meloxicam or EPA supplement plus meloxicam may be effective treatment options in the management of cancer cachexia. The combined use of these agents does not provide further advantages.
Collapse
Affiliation(s)
- Ozkan Kanat
- Department of Medical Oncology, Uludag University Faculty of Medicine, Bursa, Turkey.
| | | | | | | | | | | | | |
Collapse
|
39
|
Olmez OF, Cubukcu E, Evrensel T, Kurt M, Avci N, Tolunay S, Bekar A, Deligonul A, Hartavi M, Alkis N, Manavoglu O. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme. Clin Transl Oncol 2013; 16:173-7. [PMID: 23740136 DOI: 10.1007/s12094-013-1059-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2013] [Accepted: 05/21/2013] [Indexed: 10/26/2022]
Abstract
BACKGROUND AND AIMS Because the outcome of glioblastoma multiforme (GBM) remains dismal, there is an urgent need for a better molecular characterization of this malignancy. The aim of this prospective study was to investigate the prognostic impact of the expression of c-mesenchymal-epithelial transition (c-Met) a receptor tyrosine kinase implicated in expression growth, survival, motility/migration, and invasion in GMB patients managed according to the established diagnostic and therapeutic protocols. METHODS Between May 2003 and March 2011, a total of 69 patients (33 males and 36 females; mean age: 52.2 ± 12.9 years, age range: 23-81 years) referred to our Department for the surgical removal of GBM were evaluated immunohistochemically for c-Met expression. Progression-free survival (PFS) and overall survival (OS) served as the main outcome measures. RESULTS Compared with c-Met- subjects (n = 38), c-Met+ subjects (n = 31) had both a significantly lower OS (15.3 ± 2.3 vs. 22.6 ± 2.5 months, respectively, p < 0.01) and PFS (12.3 ± 2.1 vs. 19.1 ± 2.6 months, respectively, p < 0.05). After allowance for potential confounders, multivariate Cox regression analysis identified c-Met+ as an independent predictor of both OS (hazard ratio = 1.7; 95 % confidence interval = 1.2-1.9, p < 0.01) and PFS (hazard ratio = 1.6; 95 % confidence interval = 1.1-2.3, p < 0.05). CONCLUSIONS Our findings suggest that c-Met immunohistochemical expression is an independent predictor of outcomes in patients with GBM treated by standard of care.
Collapse
Affiliation(s)
- O F Olmez
- Department of Medical Oncology, Uludag University Medical School, Bursa, Turkey,
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Cubukcu E, Kanat O, Fatih Olmez O, Kabul S, Canhoroz M, Avci N, Deligonul A, Hartavi M, Cubukcu S, Olmez F, Kurt E, Evrensel T, Gokgoz S, Manavoglu O. Prognostic significance of estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and nm23 expression in patients with invasive breast cancer. J BUON 2013; 18:359-365. [PMID: 23818346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
PURPOSE To determine the prognostic significance of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, Ki-67, and nm23 immunohistochemical expression with respect to progression free survival (PFS) and overall survival (OS) in Turkish patients with invasive breast cancer (IBC). METHODS Patients with IBC (n = 81; mean age = 51.9 ± 11.1 years) were prospectively enrolled at the Department of Oncology, Uludag University Medical Center, Bursa, Turkey. Immunohistochemistry was performed on formalin- fixed, paraffin-embedded tissue sections. RESULTS We did not find any significant association between immunohistochemical expression of ER, PR, HER2/ neu, Ki-67, and nm23 and the baseline characteristics of IBC patients. The median patient PFS was 30 months (range 22-45), and the median OS was 32 months (range 23-46). Stratification of the patient population according to nm23 immunohistochemical expression revealed a statistically significant difference in terms of both OS (p < 0.05) and DFS (p < 0.05). Multivariate Cox regression analysis indicated that tumor grade, axillary lymph node status, and nm23 immunohistochemical expression were the 3 main independent prognostic factors for PFS and OS in IBC patients. CONCLUSION Reduced nm23 immunohistochemical expression is an independent negative prognostic factor for OS and PFS. Patients with negative nm23 expression may require a more intensive follow-up.
Collapse
Affiliation(s)
- E Cubukcu
- Department of Oncology, Sevket Yilmaz Education and Research Hospital, Bursa, Turkey
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Kurt E, Cubukcu E, Karabulut B, Olmez OF, Kurt M, Avci N, Ozdemir F, Tunali D, Evrensel T, Manavoglu O. A multi-institutional evaluation of carboplatin plus docetaxel regimen in elderly patients with advanced gastric cancer. J BUON 2013; 18:147-153. [PMID: 23613400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
PURPOSE Albeit the majority of gastric cancers occur at advanced age, little is known regarding the optimal systemic treatment of elderly patients with advanced gastric cancer (AGC). METHODS Patients with AGC who were ≥ 65 years old and were treated with carboplatin (area under the curve/AUC 5,on day 1, every 3 weeks) plus docetaxel (75 mg/m(2), on day 1, every 3 weeks) at 3 institutions were included in this retrospective analysis. The efficacy and the safety data of the regimen were analyzed. RESULTS A total of 30 patients were enrolled. They received 128 cycles of chemotherapy, with a median of 4 cycles (range 2-8). Complete response (CR) and partial response (PR) were observed in 2 (6.7%) and 10 patients (33.3%), respectively, amounting to an overall objective response rate (ORR) of 40%. Seven patients (23.3%) had disease stabilization (SD), and 11 (36.7%) showed disease progression (PD). The most common grade 3-4 toxicity was neutropenia occurring in 19 patients (63.3%). The mean progression-free survival (PFS) was 6.0 ± 0.5 months (95% CI: 5.0-7.4), and the mean overall survival (OS) 12.0 ± 1.0 months (95% CI: 9.2-12.1). CONCLUSION Carboplatin plus docetaxel seems to be an active and well-tolerated regimen, representing a valuable alternative to cisplatin- and/or fluoropyrimidine-containing regimens for the treatment of elderly patients with AGC.
Collapse
Affiliation(s)
- E Kurt
- Department of Medical Oncology, Uludag University Medical School, Bursa, Turkey
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Avci N, Kanat O, Gokgoz S, Tolunay S, Topal U, Cubukcu E, Olmez F. Activity and Safety of a Combination of Epirubicin, Docetaxel and Cisplatin as Neoadjuvant Treatment for Locally Advanced Breast Cancer (LABC): A Preliminary Report. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32922-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
43
|
Cubukcu E, Olmez OF, Avci N, Canhoroz M, Kurt E, Kanat O, Evrensel T, Manavoglu O. Identification of prognostic factors in patients with metastatic gastrointestinal stromal tumors. J BUON 2012; 17:517-521. [PMID: 23033292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
PURPOSE Gastrointestinal stromal tumors (GISTs) have a complex biology which is reflected by a marked clinical heterogeneity. Thus, there has been great interest in identifying prognostic factors influencing tumor recurrence and survival. The aim of this study was to identify potential clinical and immunohistochemical prognostic factors that may affect survival and treatment outcomes in patients with metastatic GISTs. METHODS Between 2000 and September 2011, a total of 41 patients with metastatic GISTs (29 males and 12 females; mean age: 57.4±11.8 years; range 29-74) were referred to the Department of Oncology, Uludag University Medical School. Survival analysis for a number of potential prognostic factors was made with the main outcome results of progression-free survival (PFS) and overall survival (OS7rpar;. RESULTS The most common sites of isolated metastases comprised the liver (n=18), followed by lymph nodes (n=5), the omentum (n=1), and the mesothelium (n=1). The remaining patients had metastases at multiple sites. Cox regression analysis identified ileal location as the only significant predictor of poor PFS both after first-line (p=0.023) and second-line therapy (p=0.016). Tumor location in the ileum (p=0.025) and S100 immunoreactivity (p=0.041) were both independent predictors of OS. CONCLUSION Tumor site and S100 positivity were the main significant independent predictors of clinical outcomes in patients with metastatic GISTs treated by standard of care.
Collapse
Affiliation(s)
- E Cubukcu
- Department of Oncology, Uludag University Medical School, Bursa, Turkey.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Smet PF, Avci N, Loos B, Van Haecke JE, Poelman D. Structure and photoluminescence of (Ca,Eu)(2)SiS(4) powders. J Phys Condens Matter 2007; 19:246223. [PMID: 21694066 DOI: 10.1088/0953-8984/19/24/246223] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The photoluminescence of Ca(2)SiS(4):Eu powders was investigated in detail as a function of europium concentration (from 0.1% Ca substitution to the fully substituted Eu(2)SiS(4)). At low europium dopant concentration (<10%) the powders crystallize in an orthorhombic structure and the emission spectrum is dominated by two broad emission bands, at 564 and 660 nm. The emission can be tuned from yellow (CIE x = 0.46,y = 0.53) to red (CIE x = 0.65,y = 0.35) by variation of the Eu concentration. An energetic coupling exists between both bands, leading to a broad excitation wavelength range. Powders with high europium concentration (>40%) crystallize in a monoclinic structure, details of which were determined by Rietveld refinement of x-ray diffraction data. For the composition CaEuSiS(4) (i.e. 50% substitution), the luminescence peaks at 614 nm, shifting to shorter wavelengths upon further substitution of Ca by Eu. Although considerable thermal quenching is present at room temperature in the fully Eu-substituted compound, Eu(2)SiS(4) is still photoluminescent, with a peak emission wavelength of 577 nm. A strong correlation is found between the crystallographic and luminescent properties of the (Ca,Eu)(2)SiS(4) powders. The broad emission and excitation bands make this phosphor a good candidate for use in phosphor-converted light-emitting diodes (pcLEDs).
Collapse
|
45
|
Kanyilmaz D, Erbay A, Avci N, Oztas D, Bodur H. R2252 Evaluation of reported percutaneous/mucocutaneous injuries in a tertiary care hospital. Int J Antimicrob Agents 2007. [DOI: 10.1016/s0924-8579(07)72091-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
46
|
Abstract
Serum vitamin E levels in healthy people (n = 71) and patients with cardiovascular diseases (n = 62) were determined. The cases of cardiovascular disease comprised patients with acute myocardial infarction (AMI) (n = 31), atherosclerosis (AT) (n = 23) and myocardial ischaemia (MI) (n = 8). The mean (+/- SD) serum vitamin E levels of the control group and the group with cardiovascular disease were 1.12 +/- 0.27 mg% and 0.98 +/- 0.41 mg%, respectively. Patients with AMI, AT and MI had corresponding levels of 0.97 +/- 0.48 mg%, 1.00 +/- 0.39 mg% and 1.01 +/- 0.44 mg%, respectively. Overall serum vitamin E levels were lower in the group with cardiovascular disease than in the control group. Patients and the control group are also discussed with respect to a number of potentially confounding parameters such as age, sex, smoking status, quetelet index (kg/m2), alcohol consumption, dietary intake and serum lipids.
Collapse
Affiliation(s)
- M Torun
- Department of Biochemistry, University of Gazi, Hipodrom-Ankara, Turkey
| | | | | |
Collapse
|